Literature DB >> 17003455

Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal dominant retinitis pigmentosa.

Lori S Sullivan1, Sara J Bowne, C Robyn Seaman, Susan H Blanton, Richard A Lewis, John R Heckenlively, David G Birch, Dianna Hughbanks-Wheaton, Stephen P Daiger.   

Abstract

PURPOSE: To determine whether genomic rearrangements in the PRPF31 (RP11) gene are a frequent cause of autosomal dominant retinitis pigmentosa (adRP) in a cohort of patients with adRP.
METHODS: In a cohort of 200 families with adRP, disease-causing mutations have previously been identified in 107 families. To determine the cause of disease in the remaining families, linkage testing was performed with markers for 13 known adRP loci. In a large American family, evidence was found of linkage to the PRPF31 gene, although DNA sequencing revealed no mutations. SNP testing throughout the genomic region was used to determine whether any part of the gene was deleted. Aberrant segregation of a SNP near exon 1 was observed, leading to the testing of additional SNPs in the region. After identifying an insertion-deletion mutation, the remaining 92 families were screened for genomic rearrangements in PRPF31 with multiplex ligation-dependent probe amplification (MLPA).
RESULTS: Five unique rearrangements were identified in the 93 families tested. In the large family used for linkage exclusion testing, an insertion-deletion was found that disrupts exon 1. The other four mutations identified in the cohort were deletions, ranging from 5 kb to greater than 45 kb. Two of the large deletions encompass all PRPF31 as well as several adjacent genes. The two smaller deletions involve either 5 or 10 completely deleted exons.
CONCLUSIONS: In an earlier long-term study of 200 families with adRP, disease-causing mutations were identified in 53% of the families. Mutation-testing by sequencing missed large-scale genomic rearrangements such as insertions or deletions. MLPA was used to identify genomic rearrangements in PRPF31 in five families, suggesting a frequency of approximately 2.5%. Mutations in PRPF31 now account for 8% of this adRP cohort.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003455      PMCID: PMC2778205          DOI: 10.1167/iovs.06-0440

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

1.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

2.  Multiplex ligation-dependent probe amplification using a completely synthetic probe set.

Authors:  Rowena F Stern; Roland G Roberts; Kathy Mann; Shu C Yau; Jonathan Berg; Caroline Mackie Ogilvie
Journal:  Biotechniques       Date:  2004-09       Impact factor: 1.993

3.  Evidence that the penetrance of mutations at the RP11 locus causing dominant retinitis pigmentosa is influenced by a gene linked to the homologous RP11 allele.

Authors:  T L McGee; M Devoto; J Ott; E L Berson; T P Dryja
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

4.  Genetic analysis of the guanylate cyclase activator 1B (GUCA1B) gene in patients with autosomal dominant retinal dystrophies.

Authors:  A M Payne; S M Downes; D A Bessant; C Plant; T Moore; A C Bird; S S Bhattacharya
Journal:  J Med Genet       Date:  1999-09       Impact factor: 6.318

Review 5.  Alu repeats and human disease.

Authors:  P L Deininger; M A Batzer
Journal:  Mol Genet Metab       Date:  1999-07       Impact factor: 4.797

6.  A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11).

Authors:  E N Vithana; L Abu-Safieh; M J Allen; A Carey; M Papaioannou; C Chakarova; M Al-Maghtheh; N D Ebenezer; C Willis; A T Moore; A C Bird; D M Hunt; S S Bhattacharya
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

7.  Epidemiology of retinitis pigmentosa in Denmark.

Authors:  Marianne Haim
Journal:  Acta Ophthalmol Scand Suppl       Date:  2002

8.  Evidence for a major retinitis pigmentosa locus on 19q13.4 (RP11) and association with a unique bimodal expressivity phenotype.

Authors:  M Al-Maghtheh; E Vithana; E Tarttelin; M Jay; K Evans; T Moore; S Bhattacharya; C F Inglehearn
Journal:  Am J Hum Genet       Date:  1996-10       Impact factor: 11.025

9.  Expression of PRPF31 mRNA in patients with autosomal dominant retinitis pigmentosa: a molecular clue for incomplete penetrance?

Authors:  Eranga N Vithana; Leen Abu-Safieh; Lucia Pelosini; Elizabeth Winchester; Dan Hornan; Alan C Bird; David M Hunt; Stephen A Bustin; Shomi S Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-10       Impact factor: 4.799

10.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

View more
  47 in total

1.  Investigating the mechanism of disease in the RP10 form of retinitis pigmentosa.

Authors:  Catherine J Spellicy; Dong Xu; Garrett Cobb; Lizbeth Hedstrom; Sara J Bowne; Lori S Sullivan; Stephen P Daiger
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 2.  Perspective on genes and mutations causing retinitis pigmentosa.

Authors:  Stephen P Daiger; Sara J Bowne; Lori S Sullivan
Journal:  Arch Ophthalmol       Date:  2007-02

3.  Mutations in known genes account for 58% of autosomal dominant retinitis pigmentosa (adRP).

Authors:  Stephen P Daiger; Lori S Sullivan; Anisa I Gire; David G Birch; John R Heckenlively; Sara J Bowne
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

4.  Exome-based mapping and variant prioritization for inherited Mendelian disorders.

Authors:  Daniel C Koboldt; David E Larson; Lori S Sullivan; Sara J Bowne; Karyn M Steinberg; Jennifer D Churchill; Aimee C Buhr; Nathan Nutter; Eric A Pierce; Susan H Blanton; George M Weinstock; Richard K Wilson; Stephen P Daiger
Journal:  Am J Hum Genet       Date:  2014-02-20       Impact factor: 11.025

5.  Time Course of Disease Progression of PRPF31-mediated Retinitis Pigmentosa.

Authors:  Kelly Kiser; Kaylie D Webb-Jones; Sara J Bowne; Lori S Sullivan; Stephen P Daiger; David G Birch
Journal:  Am J Ophthalmol       Date:  2018-12-21       Impact factor: 5.258

Review 6.  Genetic characterization and disease mechanism of retinitis pigmentosa; current scenario.

Authors:  Muhammad Umar Ali; Muhammad Saif Ur Rahman; Jiang Cao; Ping Xi Yuan
Journal:  3 Biotech       Date:  2017-07-18       Impact factor: 2.406

7.  Breakpoint characterization of a novel approximately 59 kb genomic deletion on 19q13.42 in autosomal-dominant retinitis pigmentosa with incomplete penetrance.

Authors:  Linda Köhn; Sara J Bowne; Lori S Sullivan; Stephen P Daiger; Marie S I Burstedt; Konstantin Kadzhaev; Ola Sandgren; Irina Golovleva
Journal:  Eur J Hum Genet       Date:  2008-12-03       Impact factor: 4.246

Review 8.  Genes and genetics in eye diseases: a genomic medicine approach for investigating hereditary and inflammatory ocular disorders.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2018-01-18       Impact factor: 1.779

9.  A single-base substitution within an intronic repetitive element causes dominant retinitis pigmentosa with reduced penetrance.

Authors:  Thomas Rio Frio; Terri L McGee; Nicholas M Wade; Christian Iseli; Jacques S Beckmann; Eliot L Berson; Carlo Rivolta
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

10.  Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa.

Authors:  Jennifer D Churchill; Sara J Bowne; Lori S Sullivan; Richard Alan Lewis; Dianna K Wheaton; David G Birch; Kari E Branham; John R Heckenlively; Stephen P Daiger
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-19       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.